Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ABL Bio Inc.
DescriptionBispecific antibody targeting delta-like 4 (DLL4) and vascular endothelial growth factor (VEGF)
Molecular Target Delta-like 4 (DLL4) ; Vascular endothelial growth factor (VEGF)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today